14 August 2018
Visiongain’ has launched a new pharma report Anti-Ageing Cosmeceuticals 2017-2027: Anti-wrinkle, Anti-stretch Mark, UV Absorbers, Hair, Topical, Invasive, Acne Therapy, Liposuction, Breast Augmentation, Hair Growth, Eyelid Surgery, Botox, Anti-pigmentation, Abdominoplasty, Other Services
Cosmeceuticals are the future generation of cosmetics and personal care industry as they not only improve appearance but also provide necessary nutrients and drug-like properties to the skin. The core properties of cosmeceuticals may be considered as hybrid of traditional cosmetics and medicines or drugs. Technological advancements have resulted in the launch of advanced and more value-added anti-ageing products in the market.
The lead analyst of the report commented “The growth in per capita disposable income, increasing baby boomer population and rising demand in anti-ageing products due to pollution and fluctuating climatic conditions have boosted the growth of anti-ageing cosmeceuticals market. Furthermore, advertisement and promotional activities from companies have strongly influenced the purchasing power and behaviours of consumers.”
Leading companies featured in the report include Allergan PLC, Avon Products Inc.
Beiersdorf AG, Chanel International B.V., Christian Dior SE, Johnson & Johnson, L'ORÉAL S.A., PROCTER & GAMBLE, Revlon Inc., Unilever PLC.
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to firstname.lastname@example.org or call her on +44 (0) 207 336 6100
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-to-business reports cusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
Demand in the early years of the forecast period will come from multinational biotech looking to sign deals with Indian companies and take advantage of the cheaper costs of production for the emerging market.
08 January 2021
The growth can be attributed to the rising prevalence of respiratory diseases, growing awareness for respiratory diseases, and innovations in respiratory and anesthesia devices. However, unfavourable reimbursement policies and lack of patient adherence in respiratory diseases are some of the factors restraining the growth of the anesthesia and respiratory devices market.
07 January 2021
Factors such as rise in the prevalence of the infectious and bacterial diseases and active participation of government in vaccine development are driving the growth of this market. While high cost of vaccine development is the key factor emerging as a growth barrier over years in this market.
07 January 2021
The potential of microbiome-based drugs as novel treatments to address the unmet needs for many diseases has contributed intensively to the rapid emergence of many investors in this area. Currently, no regulatory framework exists and no drugs have received FDA approval. However, there are several preclinical and clinical-stage companies working with various approaches to develop microbiome-based therapies.